Key insights
- Truist raised its price target on Edwards Lifesciences (EW) to $90 based on strong TAVR growth and raised fiscal 2026 guidance. The firm noted EW's revenue and earnings beat, driven by double-digit TAVR momentum. While maintaining a Hold rating, Truist acknowledges EW's premium valuation and potential for further upside from TMTT inflection beyond 2026. The report suggests continued positive momentum for EW, potentially benefiting the healthcare sector, but the limited target increase suggests a contained impact.
Investing.com - Truist Securities raised its price target on Edwards Lifesciences stock (NYSE:EW) to $90 from $89 while maintaining a Hold rating.
The firm said the company’s revenue and earnings beat was driven by continued double-digit TAVR momentum and upside, leading to raised fiscal 2026 revenue and earnings guidance. The quarter was described as good and clean, with the firm’s estimates for 2026-2027 increasing modestly.
TAVR is sustaining growth above 10% and incremental U.S. share capture at Medtronic’s expense should accelerate in coming quarters alongside catalysts for TAVR and TMTT in the second half of 2026-2027. The narrative firmly remains on Edwards Lifesciences’ side, according to the firm.
Truist said the valuation premium reflects approximately 10% double-digit revenue and earnings profile. The price target increase to $90 from $89 is based on higher 2027 estimates.The company’s premium valuation is evident in its P/E ratio of 44.04, though InvestingPro data suggests the stock remains undervalued based on its Fair Value analysis. With a market cap of $45.96 billion and revenue growth of 11.6% over the last twelve months, Edwards is delivering on its double-digit growth promise. InvestingPro subscribers have access to over 10 additional exclusive tips for EW, plus comprehensive Pro Research Reports covering 1,400+ top US stocks.
The firm said it would look for more conviction in a steeper revenue acceleration trajectory beyond 2026 from TMTT inflection to argue for a bigger premium versus that which the price target is based on.
In other recent news, Edwards Lifesciences reported impressive first-quarter financial results, surpassing analysts’ expectations. The company achieved a revenue of $1.65 billion, which exceeded the consensus estimate of $1.60 billion and represented a 16.7% year-over-year increase. Adjusted earnings per share stood at $0.78, outperforming the consensus forecast of $0.73. BTIG responded to these strong results by raising its price target for Edwards Lifesciences to $100 from $98, maintaining a Buy rating. Meanwhile, Canaccord adjusted its price target to $85 from $87, keeping a Hold rating. The company’s Transcatheter Aortic Valve Replacement (TAVR) sales reached $1.197 billion, surpassing the consensus of $1.164 billion. Additionally, Transcatheter Mitral and Tricuspid Therapies (TMTT) sales were reported at $173 million, exceeding the $165.1 million consensus. These developments reflect Edwards Lifesciences’ robust performance in the first quarter of 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.